Ustekinumab Biosimilar(Celltrion)

乌司奴单抗生物类似药 (Celltrion)

Report date: 2026/02/24 20:00:16

Base Information

Drug NameUstekinumab Biosimilar(Celltrion)
Drug Alias NameSteqeymaSteqeyma IVQoyvolmaCT-P43
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitorsInterleukin-12 subunit beta inhibitors
TargetsInterleukin-12Interleukin-23Interleukin-12 subunit beta
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2024/08/01
Country/TerritoryCanadaUnited StatesNew Zealand +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare Hungary KftCelltrion IncRani Therapeutics Holdings Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A